EI
NVCR icon

Ellevest Inc’s NovoCure NVCR Stock Holding History

Ellevest Inc’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-42
Closed -$3K – 1928
2022
Q3 		$3K Sell
42
-254
-86% -$19.8K ﹤0.01% 1284
2022
Q2 		$21K Buy
296
+157
+113% +$11.8K ﹤0.01% 744
2022
Q1 		$12K Buy
139
+131
+1,638% +$9.65K ﹤0.01% 848
2021
Q4 		$1K Sell
8
-119
-94% -$11.9K ﹤0.01% 1307
2021
Q3 		$15K Sell
127
-809
-86% -$122K ﹤0.01% 731
2021
Q2 		$208K Buy
936
+815
+674% +$159K 0.02% 254
2021
Q1 		$16K Buy
121
+53
+78% +$8.38K ﹤0.01% 703
2020
Q4 		$12K Buy
68
+57
+518% +$7.8K ﹤0.01% 716
2020
Q3 		$1K Buy
+11
New +$880 ﹤0.01% 1043
2020
Q2 		– Sell
-6
Closed – – 1269
2020
Q1 		$0 Sell
6
-11
-65% -$869 ﹤0.01% 1237
2019
Q4 		$1K Buy
+17
New +$1.37K ﹤0.01% 830

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NA
Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ellevest Inc's NVCR Position: Q4 2022 in Review

Ellevest Inc sold out of NovoCure (NVCR) in Q4 2022, closing a stake of 42 shares — an estimated $3K sold.

Ellevest Inc first reported a position in NVCR in Q4 2019 and held it in 11 quarters. The position peaked at $208K in Q2 2021. 304 funds tracked by Wall St. Rank hold NVCR as of Q4 2022.

  • Ellevest Inc reported no remaining NovoCure position as of Q4 2022 after selling out during the quarter.
  • Ellevest Inc sold 42 NovoCure shares in Q4 2022, an estimated $3K.
  • Ellevest Inc first reported a position in NovoCure in Q4 2019 and held it in 11 quarters.
  • Ellevest Inc's NovoCure position peaked at $208K in Q2 2021.
  • 304 funds tracked by Wall St. Rank held NovoCure as of Q4 2022.

Based on Ellevest Inc's 13F filing for Q4 2022, filed 3 Feb 2023.